Wegovy is a registered trademark of Novo Nordisk A/S. Medicare may cover it in defined circumstances, but the answer depends on why it is prescribed and which coverage pathway applies to the beneficiary.
Important safety information: Wegovy has a boxed warning about the risk of thyroid C-cell tumors. It is contraindicated in people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. Serious risks include pancreatitis, gallbladder problems, low blood sugar, acute kidney injury, severe gastrointestinal reactions, serious allergic reactions, diabetic retinopathy complications, and increased heart rate. Review the complete official Wegovy Prescribing Information and Medication Guide with a licensed clinician.
This page is general information, not medical advice. Talk to a licensed clinician about your situation.
Two possible Medicare pathways
The first pathway is the regular Medicare Part D prescription benefit. Federal rules generally exclude medicines when used only for weight loss, but a medicine can be coverable when prescribed for another FDA-approved use that Part D can cover.
The second pathway is the Medicare GLP-1 Bridge. CMS began this temporary initiative on July 1, 2026, for certain Part D beneficiaries who meet its criteria for weight management. It operates outside the normal Part D benefit payment flow.
The correct pathway follows the real prescribed use and current CMS rules. It is not a choice made solely to obtain a preferred price. Accurate clinical information must support every request.
When regular Part D may apply
Wegovy's FDA label includes reducing the risk of cardiovascular death, heart attack, and stroke in adults who have established cardiovascular disease and either obesity or overweight. CMS identifies this as a use that can be covered through Part D.
Part D coverage is still plan-specific. The plan may review the diagnosis, labeled use, formulary status, prior authorization criteria, quantity limits, and pharmacy network. A prescription by itself does not guarantee payment.
Ask the plan to provide its current written criteria. If the drug is not on the formulary, ask about the formulary exception process. Keep the plan's coverage decision separate from the clinician's decision about whether treatment is medically appropriate.
When the Medicare GLP-1 Bridge may apply
The Bridge is designed for specified weight-management treatment that is outside the basic Part D benefit. According to current CMS Bridge guidance, a provider must submit a prior authorization and attest that the beneficiary meets defined clinical criteria.
CMS currently lists Wegovy among the eligible products and sets a $50 copay for a monthly supply for an eligible beneficiary. The program runs from July 1, 2026, through December 31, 2027, under current guidance. The copay does not count toward Part D true out-of-pocket costs.
A beneficiary does not qualify for the Bridge merely because Part D denies a use that is otherwise coverable under the basic benefit. CMS directs coverable labeled uses, including Wegovy's cardiovascular risk-reduction use, through the Part D plan and its exception processes.
How to verify the right route
Call the prescription benefit number on the Medicare card. State the exact medicine and ask how the plan handles the actual prescribed use. If the member has Medicare Advantage with drug coverage, use that plan's Part D contact.
Ask these questions:
- Is this use processed under ordinary Part D or the Bridge?
- What prior authorization form and criteria apply?
- Is the pharmacy in network and preferred?
- What cost sharing applies if approved?
- What review rights apply if the request is denied?
Document the representative's name, date, and call reference. The formal authorization and pharmacy claim are more reliable than a general web result or another member's experience.
If coverage is denied
Read the written denial before taking the next step. A denial may reflect missing records, unmet criteria, nonformulary status, an excluded use, or a pharmacy issue. Each reason has a different response.
Part D members have rights to request coverage determinations and appeals. The denial notice explains the available process and deadlines. CMS states that participation in the Bridge does not change ordinary Part D appeal rights.
Contact the plan for the rule and the clinician for accurate medical documentation. Do not alter the diagnosis or submit misleading information. If affordability may interrupt treatment, tell the clinician and pharmacist rather than changing treatment alone.
Separate program and medication costs
An approved claim can still have cost sharing. Ask whether the amount is a deductible, copay, or coinsurance and whether the pharmacy has preferred status. For the Bridge, use the current CMS rules rather than ordinary Part D assumptions.
Body Good's prices are service fees for the program described during intake. They are not the price of medication and are not a quote for any individual. Eligibility is determined by a clinician. Medication cost is separate and is not included in a Body Good service fee.
Body Good can provide coverage support by helping with benefit checks and requested paperwork. Approval and payment are determined by the plan or Bridge administrator. Assistance does not assure a favorable decision.
This site is an informational and pricing overview. It takes no payment, collects no protected health information, and operates no intake form. Intake and checkout occur on joinbodygood.com.
Frequently asked questions
Does Medicare cover Wegovy only for weight loss?
Traditional Part D rules generally exclude drugs used only for weight loss. Other labeled uses may be coverable, and the separate Medicare GLP-1 Bridge now provides a pathway for certain eligible beneficiaries using specified medicines for weight management.
Does a Part D denial make me eligible for the Bridge?
Not automatically. Bridge eligibility follows its own criteria. A use that can be covered under basic Part D remains with the Part D plan and its coverage or exception process.
Can Body Good help identify the coverage pathway?
Body Good may provide coverage support but cannot promise eligibility or payment. Start the secure clinical intake for review by a licensed clinician.
Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. Ozempic and Wegovy are registered trademarks of Novo Nordisk A/S. Body Good is not affiliated with, endorsed by, sponsored by, or authorized by Eli Lilly and Company or Novo Nordisk A/S. All trademarks are the property of their respective owners.